Detail akcie Dianthus Rg online

Business Summary: Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company engaged in designing and delivering monoclonal antibodies with improved selectivity and potency. The Company is focused on developing complement therapeutics for patients living with severe autoimmune and inflammatory diseases. Its advanced product candidate, DNTH103, is a clinical-stage, highly potent, selective and fully human monoclonal immunoglobulin G4 with picomolar binding affinity that is designed to selectively bind only to the active form of C1s. DNTH103 is engineered with YTE half-life extension technology, a specific three amino acid change in the Fc domain, and has a pharmacokinetic (PK) profile designed to support less frequent, lower dose, self-administration as a convenient S.C. injection. It is conducting three mid- to late-stage clinical trials with DNTH103 in generalized Myasthenia Gravis (gMG), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), and Multifocal Motor Neuropathy (MMN).
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Dianthus Therapeutics Inc revenues decreased 64% to $1.8M. Net loss increased 73% to $97.9M. Revenues reflect Pharmaceutical preparation segment decrease of 19% to $1.8M. Higher net loss reflects Pharmaceutical preparation segment loss increase from $29.9M to $108.4M. Basic Earnings per Share excluding Extraordinary Items decreased from -$1.79 to -$2.68.